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doi:10.1Objective: Experimental and clinical studies have suggested that intramyocardial bone marrow stem cell trans-
plantation combined with coronary artery bypass grafting might improve left ventricular function in the setting
of chronic ischemic heart disease. We therefore conducted a systematic review and meta-analysis of available
publications regarding the efficacy and safety of intramyocardial bone marrow stem cell transplantation during
coronary artery bypass grafting.
Methods: The databases PUBMED, MEDLINE, Cochrane Controlled Trials Register, and ClinicalTrials.gov
(all from their inception toMay 2009) were searched for randomized controlled trials and cohort studies of intra-
myocardial bone marrow stem cell transplantation during coronary artery bypass grafting to treat ischemic heart
disease. Six studies were included.
Results: Compared with control groups, the bone marrow stem cell transplantation group showed a significant
improvement of left ventricular ejection fraction from baseline to follow-up (5.40%; 95% confidence interval,
1.36–9.44; P ¼ .009). Moreover, the overall change of left ventricular end-diastolic volume from baseline to
follow-up favored the bone marrow stem cell therapy group (9.55 mL; 95% confidence interval, 2.82 to
21.92; P ¼ .13). Major adverse cardiovascular events, including ventricular arrhythmia and the composite of
other cardiovascular events, were not significantly different between the bone marrow stem cell therapy group
and controls (relative risk for ventricular arrhythmia¼ 0.951; 95% confidence interval, 0.389–2.325; P¼ .913;
relative risk for cardiovascular event ¼ 1.134; 95% confidence interval, 0.28–4.6; P ¼ .86).
Conclusions: Clinical evidence suggests that intramyocardial bone marrow stem cell transplantation in combi-
nation with coronary artery bypass grafting is associated with improvements of functional parameters in patients
with chronic ischemic heart disease. Furthermore, surgical intramyocardial bone marrow stem cell transplanta-
tion seems to be safe. (J Thorac Cardiovasc Surg 2011;142:911-20)Ischemic cardiomyopathy remains one of the leading
causes of morbidity and mortality worldwide.1,2 In
addition to medical therapy and surgical or interventional
revascularization strategies, intramyocardial stem cell
therapy has become a new therapeutic option for patients
with end-stage ischemic heart disease. Although the exact
underlying mechanisms remain unclear, numerous studies
in animals have shown that intramyocardial injection of
bone marrow stem cells (BMSCs) in ischemic cardiomyop-
athy is associated with an improvement of left ventricular
function and reduction of infarct scar size.3 These promis-
ing preclinical results led to several clinical trials evaluating
possible benefits of stem cell transplantation in humans.
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Sment of acute myocardial infarction, have been carried out
using interventional therapy protocols.4 Since the first intra-
myocardial stem cell transplantation during open surgery by
Stamm and colleagues5 in 2003, studies that followed were
able to prove safety and feasibility of this new therapeutic
approach. Subsequently, several prospective, randomized
controlled trials (RCTs) were launched to evaluate the effi-
cacy of BMSC injection in addition to coronary bypass sur-
gery compared with coronary artery bypass grafting
(CABG) alone in patients with chronic ischemic heart dis-
ease. Because chronic ischemic heart disease remains a do-
main of surgical therapy protocols,6 we believe it is
reasonable to analyze available studies combining intra-
myocardial BMSC transplantation with CABG separate
from studies using interventional approaches. This article
provides a summary and meta-analysis of available pro-
spective RCTs and cohort studies to further evaluate the ef-
ficacy of this new therapeutic tool for cardiac surgeons.E
T
/BMATERIALS AND METHODS
Review Question
The review question was to what extent BMSC transplantation in com-
bination with CABG affects left ventricular function in patients with
chronic ischemic heart disease compared with CABG alone.rdiovascular Surgery c Volume 142, Number 4 911
Abbreviations and Acronyms
BMSC ¼ bone marrow stem cell
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
LVEDV ¼ left ventricular end-diastolic volume
LVEF ¼ left ventricular ejection fraction
MACE ¼ major adverse cardiovascular events
RCT ¼ randomized controlled trial
RR ¼ relative risk
SD ¼ standard deviation
SE ¼ standard error
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Two reviewers (P.D and A.K.) judged the eligibility of studies in dupli-
cate and independently. Eligible trials had to fulfill the following criteria:
RCTs or cohort study design comparing routine surgical treatment of
chronic ischemic heart disease by CABG with treatment by intramyocar-
dial BMSC injection in addition to CABG; minimum of 3-month follow-
up after stem cell therapy; and intramyocardial injection of BMSCs into
ischemic area. Exclusion criteria were intracoronary stem cell injection
and catheter-based injection methods; stem cell injection without CABG;
treatment of acute myocardial infarction; RCTs and cohort studies with
incomplete left ventricular ejection fraction (LVEF) data; and stem or pro-
genitor cells derived from other sources than bone marrow.
Search Strategy
To identify relevant studies, the electronic databases PUBMED, MED-
LINE, Cochrane Controlled Trials Register, and ClinicalTrials (all from
their inception to May 2009) were searched with the following database-
appropriate terms: bone marrow, stem cells, progenitor cells, intramyocar-
dial, coronary artery bypass surgery, CABG, transplantation, and trial.
Language restrictions were not imposed. Reference lists of identified arti-
cles and relevant review articles on the topic were also reviewed. Finally,
the included articles were limited to English description, and articles on an-
imal experiments were excluded.
Data Abstraction
Two reviewers (P.D. and A.K.) independently assessed included studies
according to author of the study, year of publication, geographic location of
the study, study type, study population, follow-up period, treatment
group, control group, LVEF at baseline (LVEFbaseline) and follow-up
(LVEFfollow-up), LVEF change from baseline to follow-up for the treatment
(LVEFBMSC change) and the control group (LVEFcontrol change), left ventric-
ular end-diastolic volume at baseline (LVEDVbaseline) and follow-up
(LVEDVfollow-up), and LVEDV change from baseline to follow-up. More-
over, the number of bypass grafts performed, number of ischemic/akinetic
territories, target areas of cell injection, and timing of CABG with com-
bined cell therapy after infarction were assessed (Tables 1–4). The major
adverse cardiovascular events (MACE) (Table 5) include ventricular
arrhythmias and the composite of other serious cardiovascular events
(cardiac death, recurrent myocardial infarction, additional coronary revas-
cularization procedures, and stroke). Relevant data were extracted from the
included articles, put into tables, and combined according to the composite
outcome definition.
Quality Assessment
The Jadad Score7 was used to grade the methodological quality of the
included studies (Table 1).912 The Journal of Thoracic and Cardiovascular SurgStatistical Analysis
For statistical data analysis, STATA 9.0 software (StataCorp, College
Station, TX) was used. All P values resulted from 2-sided statistical tests.
The analysis was stratified by the difference between the BMSC group
and the CABG control group of every study. Each mean difference was
weighted in accordance to the inverse of its variances before being pooled
with the fixed-effects model.
Our analyses were based on the 2 parameters mean difference
LVEFchange (with mean difference LVEFchange ¼ LVEFBMSC change –
LVEFcontrol change, LVEFBMSC change ¼ LVEFBMSC follow-up – LVEFBMSC
baseline, LVEFcontrol change ¼ LVEFcontrol follow-up – LVEFcontrol baseline) and
mean difference LVEDVchange, as well as their 95% confidence intervals
(CIs). In most studies, mean and standard deviation (SD) were reported.
In one trial,8 LVEFbaseline and LVEFfollow-up were expressed as mean and
standard error (SE). SE was transformed into SD by using the known
formula SD ¼ SEOn, with n being the number of observations.
Unfortunately, mean and SD of the LVEFBMSC change and LVEFcontrol
change were missing in particular studies.
8-10 Naturally, the mean of
LVEFBMSC change and LVEFcontrol change can be easily obtained by
calculating the difference between the means of LVEFbaseline and
LVEFfollow-up. However, available information of measurements of
LVEFbaseline and LVEFfollow-up allow valid calculation of SD of change
from baseline to follow-up point in time only in case the value of correla-
tion coefficient is known. Therefore, we used the reported SD of
LVEFBMSC change and LVEFcontrol change in the study of Stamm and
colleagues11 to calculate the correlation coefficients, within each group,
BMSC and control, by
R ¼ SD
2
baselineþ SD2followup SD2change
23 SDbaseline3 SDfollowup
;
following Kang and colleagues.12
The calculation resulted in R¼ 0.45 for the BMSC group and R ¼ 0.85
for the control group. By imputing these values, we calculated SD of
LVEFBMSC change and LVEFcontrol change for these 3 studies
8-10 by means
of the modified latter formula:
SDchange ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SD2baselineþ SD2followup

23R3 SDbaseline 3 SDfollowup
q
:
Overall homogeneity of the included studies was examined with Co-
chran’s chi-square test and furthermore with I2 for quantifying the effect
of heterogeneity by a percentage measure of total variation across studies,
which is due to heterogeneity rather than chance.13 The decision for appli-
cation of a fixed-effects model or a random-effects model was made on the
basis of the result of Cochran’s chi-square test. If evidence of heterogeneity
was found, a meta-regression analysis was realized to analyze how factors
such as baseline LVEF, age, and sex (% male) might alter treatment effec-
tiveness, that is, to estimate interaction between covariate and treatment. To
test the statistical significance of the overall effect of all studies, we per-
formed the z-test. The presence of publication bias was assessed by funnel
plots, Begg’s rank correlation test (t), and Egger’s weighted regression
method to quantify asymmetry in funnel plots, if substantial.
For MACE analysis, we calculated relative risk (RR) and the corre-
sponding SE by using the method of Armitage and colleagues14 to handle
the zero-cells problem.
RESULTS
Fourteen studies were identified that compared intramyo-
cardial injection of BMSCs in addition to standard revascu-
larization with standard surgical revascularization
procedures alone in patients with chronic ischemic heart
disease (Figure 1). After more detailed evaluation, 8 studies
were excluded from the meta-analysis: Seven studies usedery c October 2011
TABLE 1. Characteristics of included studies
Study
(author, year)
Sample
size
Study
design
Treatment group
(no. and type
of cells
transplanted)
Control
group
Inclusion
criteria
LVEF/LVEDV
evaluation
Follow-up
(mo)
No. of
patients
followed up
Jadad
score
Stamm and
colleagues
2007, Germany
40 RCT CD 133 BMSC
5.80 3 106
(median)
CABG only History of MI,
indication
for CABG,
akinetic
LV area
Echocardiography 6 39 4*
Hendrikx and
colleagues
2006, Belgium
20 RCT BMC-MN
60.25  31.35 3 106
CABG only History of MI,
indication
for CABG,
akinetic
LV area
Cardiac MRI 4 20 3*,y
Ahmadi and
colleagues
2007, Iran
27 Cohort CD 133 BMSC
1.89  0.03 3 106
CABG only History of MI,
indication
for CABG,
4 nonviable
segments in
LAD territory
Echocardiography 6 27 3*,y
Mocini and
colleagues
2006, Italy
36 Cohort BMC-MN
292  232 3 106
CABG only History of
MI, CABG
Indication,
nonviable
infarct area
Echocardiography 3 36 3*,y
Patel and
colleagues
2005, United
States
20 RCT CD 34 BMSC
22.0 3 106
(median)
CABG only
(off-pump)
Ischemic heart
failure,
LVEF  40%,
NYHA III-IV
Echocardiography 6 20 4*
Zhao and
colleagues
2008, China
36 RCT BMC-MN
6.59  5.12 3 108
CABG only History of MI,
akinetic
LV area,
multivessel
disease
Echocardiography 6 36 4*
BMSC, Bone marrow stem cell; BMC-MN, bone marrow mononuclear cell; CD, cluster of differentiation; CABG, coronary artery bypass grafting; LAD, left anterior descending
coronary artery; LV, left ventricle; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction;MI, myocardial infarction;MRI, magnet resonance im-
aging; RCT; randomized controlled trial; SPECT, single photon emission computed tomography. In Jadad Quality score, the highest total score is 5. Values are given as mean SD
unless otherwise specified.*Points were deducted from Quality score because the method of blinding was not described or not appropriate. yPoints were deducted from Quality
score because the method of randomization was not described or not appropriate.
Donndorf et al Evolving Technology/Basic Sciencecatheter-based endocardial or intracoronary stem cell appli-
cation methods, and no CABG was performed in one study.
Because this restrictive selection process was aimed at
emerging as far as possible congruent, and consequently
comparable available studies, 6 studies (4 RCTs9,11,15,16
and 2 cohort studies8,10) with a total of 179 patients were
included. Four of the 6 studies had a Jadad score of 4, and
2 studies had a Jadad score of 3 (Table 1). The inter-
reviewer agreement on study eligibility was 100%.E
T
/B
SStudy Characteristics
The enrolled patients’ average age ranged from 48.6 to
64.9 years in the trials, and each trial enrolled mostly
men. Notably, the sample size in each study ranged from
20 to 40 patients (median, 32), and the follow-up duration
was 3 to 6 months (median, 6 months). The proportion of
followed-up patients was more than 98.5%. There was
considerable heterogeneity in the timing of CABG with
combined cell transplantation after myocardial infarction,The Journal of Thoracic and Caranging from 7 to 84 weeks. In the selected studies,
LVEF and LVEDV were evaluated with echocardiogra-
phy8-11,16 or cardiac magnetic resonance imaging.15 As-
sessment of baseline LVEF was performed preoperatively
after enrollment for the respective study. There was no sig-
nificant difference between the control and the treatment
groups regarding the number of bypasses. One study did
not report the number of grafts performed.8 All studies
targeted the infarct border zone for stem cell injection;
cells were also injected into the infarct area in only 1
study.10Meta-Analysis and Efficacy
Homogeneity test revealed rejection of null hypothesis of
homogeneity for LVEFchange (Cochran’s c
2 test, P<.001,
Figure 2) and a nonsignificant result for LVEDVchange
(Cochran’s c2 test, P ¼ .485, Figure 3). Therefore,
a random-effects model for LVEFchange and a fixed-effects
model for LVEDVchange were applied.rdiovascular Surgery c Volume 142, Number 4 913
TABLE 2. Perioperative and intraoperative characteristics of studies included in meta-analysis
No. of patients No. of bypasses
No. of ischemic/akinetic
territories Target of cell injection Infarct age (wks)
Study Treatment Control Treatment Control Treatment Control Treatment Control Treatment Control
Stamm and
colleagues
2007, Germany
20 20 3.3  1.3 3.6  0.8 1 1 Peri-infarct peri-infarct 9 (2–1200) 7.5 (2–830)
(median and range)
Hendrikx and
colleagues
2006, Belgium
10 10 2.8  0.4 2.5  0.5 n.a n.a. Peri-infarct peri-infarct 31.0  23.2 30.4  20.7
Ahmadi and
colleagues
2007, Iran
18 9 n.a. n.a. 4.78  0.26 4.67  0.47 Peri-infarct peri-infarct 10.5  0.2 10.6  0.3
Mocini and
colleagues
2006, Italy
18 18 2.1. 3.0 (median) n.a. n.a. Peri-infarct
þ Infarct
peri-infarct
þ Infarct
n.a. n.a.
Patel and
colleagues 2005,
United States
10 10 1.1  0.3 1.0  0.0 n.a. n.a. Peri-infarct peri-infarct n.a. n.a
LITA-LAD only (19),
additional
vein graft (1)
Zhao and
colleagues
2008, China
18 18 3.68  1.32 3.75  1.83 1 1 Peri-infarct peri-infarct 72.0  66.8 84.0  72.8
LITA, Left internal thoracic artery; LAD, left anterior descending artery; n.a., not announced. Values are given as mean  SD unless otherwise specified.
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regarding the overall change of the LVEF (LVEFchange)
from baseline to follow-up between BMSC therapy and
control, favoring the BMSC therapy group (5.40%; 95%
CI, 1.36–9.44; P ¼ .009; Figure 2).TABLE 3. Treatment results of studies included in the meta-analysis: Left
No. of patients Age (y) Sex, male (%
Study Treatment Control Treatment Control Treatment Con
Stamm and
colleagues
2007,
Germany
20 20 62.0  10.2 63.5  8.4 75 80
Hendrikx and
colleagues
2006,
Belgium
10 10 63.2  8.5 66  9.2 100 70
Ahmadi and
colleagues
2007, Iran
18 9 48.6  9.8 50.9  4.7 91.6 57
Mocini and
colleagues
2006, Italy
18 18 64.4  8.6 66.9  4.5 94.4 94
Patel and
colleagues
2005,
United States
10 10 64.8  3.9 63.6  4.9 80 80
Zhao and
colleagues
2008, China
18 18 60.3  10.4 59.1  15.7 83.3 83
LVEF, Left ventricular ejection fraction. Values are given as mean  SD unless otherwise
914 The Journal of Thoracic and Cardiovascular SurgBecause of evidence for heterogeneity, a meta-regression
analysis was realized for LVEFchange. The regression coef-
ficients are the estimated change in the LVEFchange per
unit change in the covariates. LVEFchange is estimated to in-
crease by 0.64 per year of age and to decrease by 0.50 perventricular ejection fraction
)
Baseline
LVEF (%)
Follow-up
LVEF (%)
Change of
LVEF (%)
trol Treatment Control Treatment Control Treatment Control
37.4  8.4 37.9  10.3 47.1  8.3 41.3  9.1 9.7  8.8 3.4  5.5
42.9  10.3 39.5  5.5 48.9  9.5 43.1  10.9 6.1  8.6 3.6  9.1
.1 34.3  6.4 29.2  7.8 38.0  5.5 34.3  8.4 3.7  6.3 5.1  4.5
.4 46.0  6 48.0  8 51.0  9 49.0  9 5.0  8.3 1.0  4.8
29.4  3.6 30.7  2.5 46.9  1.9 37.2  3.4 16.7  3.2 6.5  1.8
.3 35.8  7.3 36.7  9.2 49.1  9.7 40.6  8.4 13.3  9.2 3.9  4.9
specified.
ery c October 2011
TABLE 4. Treatment results of studies included in the meta-analysis: Left ventricular end-diastolic volume
No. of patients Age (y) Sex, male (%)
Baseline
LVEDV (mL)
Follow-up
LVEDV (mL)
Change of
LVEDV (mL)
Study Treatment Control Treatment Control Treatment Control Treatment Control Treatment Control Treatment Control
Stamm and
colleagues
2007,
Germany
20 20 62.0  10.2 63.5  8.4 75 80 153.9  28 153.7  35 142.8  42.0 149.3  35 11.1  38.6 4.4  19.2
Ahmadi and
colleagues
2007, Iran
18 9 48.6  9.8 50.9  4.7 91.6 57.1 110.6  7.5 137.5  25.7 108.0  9.6 129.6  16.6 2.6  9.17. 9  14.5
Patel and
colleagues
2005,
United States
10 10 64.8  3.9 63.6  4.9 80 80 143.0  29.0 144.0  23.0 121.0  26.0 139.0  22.0 22.0  27.6 5.0  12.4
LVEDV, Left ventricular end-diastolic volume. Values are given as mean  SD unless otherwise specified.
Donndorf et al Evolving Technology/Basic Scienceunit increase of baseline LVEF. Although the association
between LVEFchange and age is of strong statistical evidence
(z-test for regression coefficient, P ¼ .021), the association
between LVEFchange and baseline LVEF could not be de-
tected significantly (P ¼ .248).
Moreover, BMSC therapy showed a trend toward a reduc-
tion in LVEDV compared with the control group, with the
overall change of LVEDV (LVEDVchange) from baseline
to follow-up favoring the BMSC therapy group (9.55 mL;
95% CI,2.82 to 21.92; P ¼ .13; Figure 3).
To exclude potential publication bias, Begg’s rank corre-
lation test and Egger’s weighted regression test for publica-
tion bias were performed. No publication bias was evident
for the 6 studies included in LVEF meta-analysis (Begg’s
rank correlation P ¼ .573 for mean difference LVEFchange;
Egger’s weighted regression P ¼ .126 for mean difference
LVEFchange) or the 3 studies included in the LVEDV
meta-analysis (Begg’s rank correlation P ¼ .117 for mean
difference LVEDVchange; Egger’s weighted regression
P ¼ .415 for mean difference LVEDVchange).TABLE 5. Summary of reported major adverse cardiovascular events dur
No. of patients Follow-up (mo)
Study Treatment Control Treatment Contr
Stamm and colleagues
2007, Germany
20 20 6 6
Hendrikx and colleagues
2006, Belgium
10 10 4 4
Ahmadi and colleagues
2007, Iran
18 9 6 6
Mocini and colleagues
2006, Italy
18 18 3 3
Patel and colleagues
2005,
United States
10 10 4 4
Zhao and colleagues
2008, China
18 18 6 6
MI, Myocardial infarction.
The Journal of Thoracic and CaMajor Adverse Cardiovascular Events
MACE rates in all 6 studies are described in Table 4.
Furthermore, we analyzed the risk ratios of MACE between
theBMSC treatment and the control groups (Figures 4 and 5).
We found that ventricular arrhythmias and the composite of
other cardiovascular events were not significantly different
between BMSC therapy and controls (RRVA: 0.951; 95%
CI, 0.389–2.325; P ¼ .913; RRCE ¼ 1.134; 95% CI,
0.28–4.6; P ¼ .86), supposing homogeneity (c2VA ¼ 1.122,
df ¼ 5, P ¼ .952; c2CE ¼ 1.504, df ¼ 5, P ¼ .913).
DISCUSSION
This systematic review and meta-analysis, the first, to our
knowledge, summarizing the available evidence of intra-
myocardial BMSC transplantation during CABG in patients
with chronic ischemic heart disease, indicates that BMSC
transplantation in addition to CABG is safe and leads to
benefits compared with those achieved by CABG alone.
Our results suggest a potential improvement of heart func-
tion after intramyocardial BMSC transplantation, indicateding follow-up
Ventricular
arrhythmias
(patients)
Composite of cardiac death,
recurrent MI, revascularization
procedure, and stroke (patients)
ol Treatment Control Treatment Control
0 0 1 0
0 0 0 1
0 0 0 0
1 3 0 0
0 0 0 0
5 4 1 0
rdiovascular Surgery c Volume 142, Number 4 915
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FIGURE 1. Flow chart of eligible studies with BMSC transplantation in
combination with CABG in patients with chronic ischemic heart disease.
CABG, Coronary artery bypass grafting; RCT, randomized controlled trial.
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Sby improved LVEF. A trend toward reduced LVEDV in the
BMSC transplantation group suggests a decrease of cardiac
remodeling, however, without reaching statistical signifi-
cance. In terms of the functional outcome after BMSC)000.0 = p ,%7.18 = derauqs-I(  llarevO
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6002 .la te xkirdneH
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FIGURE 2. Forest plot of difference in mean with 95% CI shows improveme
compared with control group. Transplantation of BMSC in addition to CABG re
effect was statistically significant in favor of BMSC therapy. Sizes of data ma
random-effects estimate. Heterogeneity: c2 ¼ 27.28, df ¼ 5, P < .0
heterogeneity) ¼ 81.7%; significant overall effect: z ¼ 2.62, P ¼ .009.
916 The Journal of Thoracic and Cardiovascular Surgtransplantation in combination with CABG, our meta-
analysis of available studies shows an improvement of
LVEF that is significantly higher in the stem cell-treated
groups compared with groups treated with CABG only.
Meta-regression analysis performed indicates that benefi-
cial functional effects of stem cell therapy in addition to
CABG surgery are positively correlated with the amount
of preoperative LVEF depression. This underlines the fact
that surgical stem cell therapy should primarily focus on pa-
tients with indication for CABG surgery and reduced left
ventricular function due to chronic ischemia. Notably, the
age of patients was found to significantly correlate with
functional effects of cell therapy. Because intrinsic myocar-
dial regeneration takes places, but is reduced during a nor-
mal life span,17 it is conceivable that, in addition to
revascularization procedures, elderly patients especially
might profit from cell therapy aimed at stimulating regener-
ative processes.
The improvement of LVEF (mean difference LVEFchange
of 5.40%) (Figure 2) in our meta-analysis tends to be higher
than in a recently published meta-analysis of intracoronary
bone marrow transplantation in the setting of acute myocar-
dial infarction.12 This difference in functional improvement
might be due to either the different time point of BMSC
transplantation (acute myocardial infarction vs chronic is-
chemic heart disease due to old infarction) or the differing
route of cell delivery (intracoronary vs intramyocardial
cell application). Early injection after infarction could be)44.9 ,63.1( 04.5
)22.41 ,85.4( 04.9
)62.01 ,62.5-( 05.2
)34.8 ,34.0-( 00.4
)IC %59( DMW
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nt of LVEF (Mean difference LVEFchange) in patients treated with BMSC
sulted in a 5.40% (95% CI, 1.36–9.44) increase in mean LVEF. The overall
rkers represent the statistical weight each study contributed to the overall
01, and I2 (variation in weighted mean difference attributable to
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RR Ventricular Arrhythmias
.1 1 10
Major adverse cardiovascular events
Ventricular Arrhythmias
Favors BMSC Favors Control
Stamm et al. 2007
Hendrikx et al. 2006
Ahmadi et al. 2006
Moccini et al.2005
Patel et al. 2005
Zhao et al. 2006
Combined
(95% CI)
Forest Plot Fixed Effects
Study
FIGURE 4. Forest plot of RR with the corresponding 95% CI for ventricular arrhythmias in patients treated with BMSC compared with control group.
Sizes of data markers represent the statistical weight each study contributed to the overall fixed-effects estimate. The overall RR shows no significant dif-
ference between the 2 groups (RR¼ 0.951, 95% CI, 0.389–2.325, z¼0.109, P¼ .913), and the included studies are not to be considered inhomogeneous
concerning ventricular arrhythmias (c2 ¼ 1.122, df ¼ 5, P ¼ .952).
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FIGURE 3. Forest plot of difference in mean with 95% CI shows change of LVEDV (Mean difference LVEDVchange) in patients treated with BMSC com-
paredwith control groups. BMSC transplantation in addition to CABG resulted in a 9.55-mL (95%CI,2.81 to 21.92) decrease inmean LVEDV. The overall
effect favors BMSC treatment (not significant). Sizes of data markers represent the statistical weight each study contributed to the overall fixed-effects es-
timate. No heterogeneity: c2 ¼ 1.45, df ¼ 2, P ¼ .485, and I2 (variation in weighted mean difference attributable to heterogeneity) ¼ 0.0%; significant
overall effect: z ¼ 1.51, P ¼ .130.
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FIGURE 5. Forest plot of RR with the corresponding 95% CI for the composite of other cardiovascular events (cardiac death, recurrent myocardial in-
farction, additional coronary revascularization procedures, and stroke) in patients treated with BMSC compared with control group. Sizes of data markers
represent the statistical weight each study contributed to the overall fixed-effects estimate. The overall RR shows no significant difference between the 2
groups (RR¼ 1.134, 95% CI, 0.28–4.599, z¼ 0.176, P¼ .86), and the included studies are not to be considered inhomogeneous concerning the composite
of other cardiovascular events (c2 ¼ 1.504, df ¼ 5, P ¼ .913).
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Sbeneficial to prevent a large fibrotic scare. On the other
hand, because myocardial infarction leads to severe impair-
ment of heart function associated with rhythmic instability
and poorer tolerance of additional treatment, it might be
reasonable to wait for the acute phase to pass until the
infarction zone is consolidated. Furthermore, cell transplan-
tation should be more effective after the postischemic
inflammatory reaction has subsided.6,18 Stem cell
transplantation within the ‘‘hot’’ phase of post-infarction in-
flammation might lead them to take part in the inflammation
cascade rather than in the formation of vessels.19 In regard
to the route of stem cell delivery, the amount of stem cell re-
cruitment after intravascular cell application is an obvious
problem, because preclinical reports describe the myocar-
dial persistence of mononuclear cells from bone marrow
after intravascular application as ‘‘poor.’’20 Local intramyo-
cardial surgical injection might overcome the problem. In
contrast with intracoronary application, stem cells can be
delivered directly into the target area of the myocardium
without depending on sufficient cell migration across the
endothelial barrier, most likely resulting in a decrease of im-
mediate washout and remote organ engraftment of injected
cells.21 However, except for one study,15 all included trials
lack placebo injections in the control groups and none of the
studies were performed in a double-blinded way. In addition918 The Journal of Thoracic and Cardiovascular Surgto these methodological advisements, there are further lim-
itations that have to be considered when interpreting the re-
sults of our meta-analysis. Because we aimed for evaluating
specific surgical stem cell application in combination with
CABG, the number of included studies was rather small,
gaining an enhanced comparability of studies in return
and thus an increased power compared with individual stud-
ies. Nevertheless, some different study aspects remained.
The methods for evaluating LVEF and LVEDV, the interval
between myocardial infarction and CABG, the baseline
LVEF, the amount, and the specific type of BMSC used var-
ied among the included studies (Table 1). All of these form
potential sources of heterogeneity. The differing baseline
LVEF (LVEFbaseline Table 3) from 29.2%  2.6%8 to
48.0%  8.0%10 especially limits the interpretation of
LVEF data. Future multicenter trials can overcome this
problem only by setting up strict inclusion criteria regarding
preoperative LVEF. Moreover, 3 of the included 6 studies
did not use a specified population of BMSCs but injected
a semi-enriched population of bone marrow mononuclear
cells. In addition to hematopoietic and mesenchymal stem
cells, this population contains leucocytes, making it diffi-
cult to attribute functional effects to a certain cell type. Fur-
thermore, because half of the included articles lack
complete dimensional left ventricular data, LVEDV changeery c October 2011
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Swas analyzed as qualified in 3 comparable studies. It should
be noted that bypass grafting was performed without the use
of a heart-lung machine in one study.16 Although this off-
pump approach is of major interest, demonstrating that
intramyocardial stem cell injection during CABG can be
performed safely without the need for cardioplegic heart
arrest, it contributes to methodological heterogeneity. How-
ever, the consistency of the beneficial effect of BMSC trans-
plantation regarding LVEF as the primary outcome
parameter prespecified in all studies suggests that the asso-
ciation is valid. We believe that combining data from both
RCTs and cohort studies to gain adequate statistical power
was justified, because all included studies followed the
patients prospectively. It was clearly not our aim to give a fi-
nal judgment regarding the efficacy of intramyocardial cell
therapy in combination with CABG but to summarize avail-
able evidence to support the ongoing clinical research in the
field of surgical stem cell therapy for chronic ischemic heart
disease. Only critical analysis of available clinical evidence
can detect study heterogeneity and facilitate the design of
adequate surgical, double-blinded, randomized, prospective
trials because they have been already performed in a larger
extent in the field of interventional cardiac cell therapy. To
address this issue, the authors recently launched the
PERFECT trial, a double-blinded, placebo-controlled, mul-
ticenter trial comparing intramyocardial bone marrow CD
133þ stem cell injection during CABG surgery and CABG
in combination with placebo injection. The patient inclu-
sion criteria (see below) were set up after careful review
of both their own previous clinical experience6 and avail-
able clinical evidence. For accurate preoperative evaluation
of regional myocardial perfusion deficits, left ventricular
function, and consecutive detection of target areas for cell
therapy (ie, hibernating myocardium), standardized cardiac
magnetic resonance imaging examinations have been estab-
lished.
PERFECT trial (ClinicalTrials.gov Identifier:
NCT00950274)
Patient inclusion criteria:
 Coronary artery diseasewith indication for CABG and
previous myocardial infarction
 Time frame infarction to cell transplantation more
than 2 weeks
 LVEF between 25% and 40% measured by cardiac
magnetic resonance imaging
 Akinetic/hypokinetic/hibernating left ventricular
areas localized by cardiac stress magnetic resonance
imagingE
T
/BCONCLUSIONS
The results of our meta-analysis suggest that intramyo-
cardial BMSC injection in patients undergoing CABG forThe Journal of Thoracic and Caischemic heart disease is reportedly safe and associated
with an improvement of left ventricular functional and
modest improvements in dimensional parameters. These
improvements are beyond those achieved by standard surgi-
cal revascularization alone. Yet, whether the reported gain
in left ventricular function leads to long-term clinical im-
provement in these patients needs to be further clarified. Be-
cause the beneficial effects were consistent but studies
performed so far are heterogenous and lack adequate blind-
ing and statistical power, our results support the conduct of
larger, double-blinded multicenter trials, such as the
recently launched PERFECT trial, to further evaluate
long-term impact of BMSC transplantation during CABG
on cardiac function and clinical outcome in patients with
ischemic heart disease.
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